CCDR: Volume 41S-5, November 19, 2015: Antimicrobial resistance and innovation
Download the current issue as a PDF (384 KB - 16 pages)
Published by: The Public Health Agency of Canada
Date published: November 19, 2015
In this supplement: Antimicrobial resistance and innovation
In this issue, read about how normal flora can now be manufactured to treat Clostridium difficile and potentially other conditions, learn how optimal vaccine use can minimize the need for antibiotics, and see how the Canadian Institutes of Health Research has been funding research on antimicrobial resistance (AMR) innovation. In the ID News section read about the use of nanotechnologies to treat HIV, tuberculosis and yeast infections, and learn about a new protein inhibitor to treat malaria. This is the last in a series of theme issues to highlight the three pillars of Canada's Federal Action Plan on AMR: Surveillance, Stewardship and Innovation. If we all continue to work together on this three-pillar approach, the potentially devastating effects of AMR can be averted.
Table of contents
Using bugs as drugs: Microbial ecosystem therapeutics
Allen-Vercoe E, Petrof EO
Immunization as a tool to combat antimicrobial resistance
Spika J, Rud EW
The Canadian Institutes of Health Research response to antimicrobial resistance
Pagé EL, Desnoyers S, Létourneau IJ, Keown K, Jackson A, Ouellette M
March 9-12, 2016: European Society of Clinical Microbiology and Infectious Diseases (ESCMID). International Meeting on Microbial Epidemiological Markers. Navigating Microbial Genomes: Insights from the Next Generation. Estoril, Portugal.
Report a problem or mistake on this page
- Date modified: